Background
In Denmark, Omalizumab is approved for treating children with severe persistent allergic asthma older than 6 years of age. No systematic registration of the efficacy in the Danish child population according to asthma symptoms or the efficacy on co-morbid allergic symptoms exists. A broad panel of outcome measures is necessary to evaluate the efficacy of Omalizumab treatment.
Aim
To provide a standardized systematic registration in order to create a database enrolling children with severe allergic asthma treated with Omalizumab.
Method and study design
A national multicenter registration and follow-up study based on children with clinical persistent severe allergic asthma including both retrospective and prospective registration.
Inclusion criteria
Children, 6-18 years of age, with severe persistent allergic asthma according to GINA treated with Omalizumab.
Outcome registration
A broad panel of outcome measures is scheduled at baseline and during treatment:
The monitoring plan and follow-up programme will be presented in a flowchart.
Conclusion
We believe that a national systematic registration will increase knowledge regarding efficacy of Omalizumab treatment in this rare group of severe allergic asthmatic children.
